Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 6/20 | 0.38 |
| ▸ | RAB9A | P51151 | 6/20 | 0.38 |
| ▸ | LMNA | P02545 | 5/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 5/20 | 0.38 |
| ▸ | HTT | P42858 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL474116 | 1.00 | ALOX5 (0.46) | ALOX5MEN1KMT2ANPC1RAB9A | |
| SCHEMBL4143578 | 0.94 | MEN1 (0.42) | ALOX5MEN1KMT2ANPC1RAB9A | |
| SCHEMBL27064650 | 0.92 | MEN1 (0.41) | ALOX5MEN1KMT2ANPC1RAB9A | |
| SCHEMBL9440202 | 0.92 | MEN1 (0.41) | ALOX5MEN1KMT2ANPC1RAB9A | |
| SCHEMBL4141905 | 0.92 | MEN1 (0.41) | ALOX5MEN1KMT2ANPC1RAB9A | |
| SCHEMBL9440178 | 0.92 | MEN1 (0.50) | ALOX5MEN1KMT2ANPC1RAB9A | |
| SCHEMBL9440269 | 0.89 | HRH3 (0.35) | ALOX5MEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL9440237 | 0.86 | MEN1 (0.48) | ALOX5MEN1KMT2ANPC1RAB9A | |
| SCHEMBL10512029 | 0.85 | HRH3 (0.47) | MEN1KMT2AGNAI3GNAO1GNAI1 | |
| SCHEMBL9440179 | 0.84 | MEN1 (0.47) | ALOX5MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | Ananda Scientific, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| EP-0325616-B1 | PENETRATION ENHANCERS FOR TRANSDERMAL DELIVERY OF SYSTEMIC AGENTS | WHITBY RESEARCH INC (US) | 1994-07-20 | — | — | EP | disclosed |
| US-5270346-A | Penetration enhancers for transdermal delivery of systemic agents | WHITBY RESEARCH, INC. (US) | 1993-12-14 | — | — | US | disclosed |
| US-5256647-A | Enhanced penetration of skin with antibiotic, bactericides | WHITBY RESEARCH, INC. (US) | 1993-10-26 | — | — | US | disclosed |
| US-5218113-A | To enhance the penetration of physiologically active agent through the skin or other membrane | WHITBY RESEARCH, INC. (US) | 1993-06-08 | — | — | US | disclosed |
| EP-0257063-B1 | COMPOSITIONS COMPRISING 1-SUBSTITUTED AZACYCLOALKANES AND THEIR USES | WHITBY RESEARCH, Inc. (US) | 1992-06-17 | — | — | EP | disclosed |
| US-4992422-A | Enhanced penetration of skin, membranes | WHITBY RESEARCH, INC. (US) | 1991-02-12 | — | — | US | disclosed |
| EP-0325616-A4 | PENETRATION ENHANCERS FOR TRANSDERMAL DELIVERY OF SYSTEMIC AGENTS. | NELSON RES & DEV COMPANY (US) | 1989-12-12 | — | — | EP | disclosed |
| EP-0325616-A1 | PENETRATION ENHANCERS FOR TRANSDERMAL DELIVERY OF SYSTEMIC AGENTS. | NELSON RES & DEV (US) | 1989-08-02 | — | — | EP | disclosed |
| WO-1988002626-A1 | PENETRATION ENHANCERS FOR TRANSDERMAL DELIVERY OF SYSTEMIC AGENTS | NELSON RESEARCH AND DEVELOPMENT COMPANY (US) | 1988-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | CNR2, CNR1, FAAH | ALOX5 34/4885MEN1 4840/4885KMT2A 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.